Jonathan M. Meyer, MD, DLFAPA

Dr Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.

Innovative approaches enhance understanding of tardive dyskinesia's impact on patients' lives, shifting focus from detection to functional well-being.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

In this CME article, learn more about alternative methods to screen for lithium-related polyuria and how to implement amiloride for lithium-related polyuria.

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

In this CME article, review management of several clozapine-related adverse effects and outline considerations when addressing inadequate positive symptom response to clozapine.

In this CME article, read more about best practices for utilizing clozapine plasma levels and the clozapine/norclozapine ratio to monitor clozapine therapy.

Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

Which treatment approaches are the state-of-the-art for helping this patient population?

The Metabolic Syndrome and Schizophrenia: Clinical Research Update

The atypical antipsychotics have become the treatment of choice for patients with psychotic and other behavioral disorders. However, case reports, retrospective studies and epidemiological data suggest that these medications may be associated with new-onset type 2 diabetes and diabetic ketoacidosis.